Error loading player: No playable sources found
47178
M4Q and Digital Regulatory Assessment
Date
October 17, 2022
This product is not available for individual purchase, but it is available as part of the following products:
Digitalisation is already transforming industries and its application in the world of regulatory assessment is on the horizon. Multiple recent efforts have focused on digitalisation and its potential to increase efficiency in submission and review, for both industry and agencies. Initiatives such as Accumulus, data standardization, and the revision of M4Q are all intended to facilitate global harmonization, thereby enhancing submission efficiency, regulatory assessment, and enabling pharmaceutical supply to patients worldwide. This session will focus on several key efforts in this space and will explore the specific activities ongoing in each, as well as reflections from Industry and Regulatory Agencies perspectives.
Session Speakers:
EMA Perspectives on ICH M4Q(R2) and Digital Regulatory Assessments
Klara Tiitso, EMA-European Medicines Agency, Netherlands
FDA Perspective on Opportunities for Modernization of Regulatory Submissions
Ingrid Markovic, CBER, FDA, United States
M4Q ICH Current Status and Vision from Industry
Sarah Pope Miksinski, AstraZeneca, United States
The Power of Data Exchange CMC Interoperability and a Cloud-based Ecosystem
Michael Abernathy, Amgen Inc., United States
Session Speakers:
EMA Perspectives on ICH M4Q(R2) and Digital Regulatory Assessments
Klara Tiitso, EMA-European Medicines Agency, Netherlands
FDA Perspective on Opportunities for Modernization of Regulatory Submissions
Ingrid Markovic, CBER, FDA, United States
M4Q ICH Current Status and Vision from Industry
Sarah Pope Miksinski, AstraZeneca, United States
The Power of Data Exchange CMC Interoperability and a Cloud-based Ecosystem
Michael Abernathy, Amgen Inc., United States
Related Products
The Acceptance of Modelling Approaches
Over recent years, an increasing number of medicines have been developed for orphan indications and for treatment of unmet clinical need. The abbreviated development times associated with such clinical programmes has required sponsors to expedite CMC activities…
Efficiency Toolbox - Development & Lifecycle Management
Accelerated CMC and regulatory efficiency tools can be used to support the approval of medicines in early access programmes, such as emergency medicines and medicinal products for unmet medical need…
New Technologies for Analytical Control - Multi-attribute Methodology, HCP-MS, etc.
To meet the demands of increasingly complex medicinal products, technologies like mass spectrometry are needed – also in a QC lab. However, for methods like MAM by LC-MS and HCP by MS little experience on how to handle mass spectrometry in a QC lab is currently available…
Innovation for Products and Processes
There are lots of exciting developments and innovations for biopharma products and processes that have the potential to transform healthcare treatment and delivery…
